D. Fischer

Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.

M. Rezai, T. Fehm, S. Loibl, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Avoiding OHSS: Controlled Ovarian Low-Dose Stimulation in Women with PCOS

P. Wimberger, D. Fischer, M. Goeckenjan, 2016, Geburtshilfe und Frauenheilkunde.

ZORO: A prospective randomized multicenter study to prevent chemotherapy-induced ovarian failure with the GnRH-agonist goserelin in young hormone-insensitive breast cancer patients receiving anthracycline containing (neo-) adjuvant chemotherapy (GBG 37).

S. Loibl, H. Sommer, B. Gerber, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.

M. Rezai, T. Fehm, T. Kühn, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.

M. Rezai, T. Fehm, S. Loibl, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NOGGO Ov-42/MAMOC: Rucaparib maintenance after bevacizumab maintenance following carboplatin-based first line-chemotherapy in ovarian cancer patients.

F. Marmé, I. Runnebaum, J. Sehouli, 2020 .